A detailed history of Advisor Group Holdings, Inc. transactions in Bio Atla, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 1,400 shares of BCAB stock, worth $1,890. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,400
Previous 4,500 68.89%
Holding current value
$1,890
Previous $6,000 66.67%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$1.17 - $2.05 $3,627 - $6,354
-3,100 Reduced 68.89%
1,400 $2,000
Q2 2024

Aug 13, 2024

BUY
$1.37 - $3.92 $4,795 - $13,720
3,500 Added 350.0%
4,500 $6,000
Q1 2024

May 10, 2024

SELL
$1.88 - $3.46 $29,880 - $54,993
-15,894 Reduced 94.08%
1,000 $3,000
Q4 2023

Feb 12, 2024

BUY
$1.27 - $3.18 $21,455 - $53,722
16,894 New
16,894 $41,000
Q4 2020

Feb 10, 2021

BUY
$31.02 - $35.16 $1,551 - $1,757
50 New
50 $2,000

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $49M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.